Eli Lilly & Co. (LLY) announced Wednesday morning that its Phase 3 study of solanezumab did not meet the primary endpoint in patients with mild dementia due to Alzheimer's disease. The company said it will not pursue regulatory submissions for the drug.
from RTT - Before the Bell http://ift.tt/2fvhkZq
via IFTTT
No comments:
Post a Comment